Antibiotic resistance poses a critical global health threat, necessitating new strategies to address multidrug-resistant bacteria. This study presents the in silico design and evaluation of five novel benzimidazole derivatives (B1–B5) as dual-action inhibitors targeting both the AcrB efflux pump and NDM-1 carbapenemase two major contributors to antibiotic resistance in Gram-negative pathogens. Computational tools, including Chemdraw, Spartan14, Chimera, Autodock Vina, and Biovia Discovery Studio, were employed for molecular modeling, docking, and visualization of key molecular interactions. All compounds satisfied Lipinski’s rule of five, exhibited high predicted gastrointestinal absorption, and demonstrated favorable pharmacokinetic profiles. Toxicity assessments indicated low to moderate risk, with B4 identified as the safest candidate (LD50: 3420 mg/kg). Molecular docking revealed that B1 and B5 displayed superior binding affinities to NDM-1 (-6.9 and -7.0 kcal/mol, respectively), outperforming the native ligand, while B3 and B4 matched or exceeded the native ligand’s binding to AcrB (-11.1 and -11.0 kcal/mol). Detailed interaction analysis highlighted the importance of hydrogen bonds, pi-alkyl, and pi-pi stacking in stabilizing these complexes. These findings suggest that the designed benzimidazole derivatives hold promise as dual-target inhibitors, offering a potential pathway for developing new therapeutics to combat antibiotic resistance. Further experimental validation is recommended to confirm these computational results and advance these candidates toward clinical application.
Cancer remains a leading cause of mortality in sub-Saharan Africa, with limited access to targeted therapies driving demand for affordable, novel lead compounds. Irvingia gabonensis (Aubry-Lecomte ex O’Rorke) Baill., known as ogbono or African bush mango, is a nutritional staple across West and Central Africa whose seed harbours bioactive phytochemicals. Molecular docking studies were conducted using AutoDock Vina (version 1.2.0) against three oncogenic targets: Bcl-2 (PDB: 6O0K), phosphoinositide 3-kinase gamma (PI3K-gamma; PDB: 1E8X), and the nuclear factor kappa-B p65 subunit (NF-kB p65; PDB: 2RAM). Five phytocompounds, namely ellagic acid, quercetin, kaempferol, lupeol, and beta-sitosterol, were evaluated alongside three reference drugs: venetoclax, idelalisib, and BAY 11-7082. Pharmacokinetic profiling was assessed through Lipinski, Veber, and Ghose drug-likeness filters, and ADMET properties were predicted using computational descriptors. Quercetin exhibited the highest binding affinity among phytocompounds, recording −9.1 kcal/mol against PI3K-gamma and −8.9 kcal/mol against Bcl-2, approaching reference idelalisib (−9.8 kcal/mol). Kaempferol and ellagic acid demonstrated consistent multi-target engagement across all three proteins. Four of five phytocompounds satisfied Lipinski criteria with zero or one violation. ADMET analysis revealed favourable safety profiles relative to reference drugs, with no predicted hERG inhibition or hepatotoxicity across phytocompounds. The phytocompound matrix of I. gabonensis seeds constitutes a computationally validated multi-target oncological scaffold. Quercetin and kaempferol emerge as the most promising phytocompounds for further experimental investigation. This study provides a reproducible computational framework and advances the case for repositioning an African food crop as a natural product lead in cancer drug discovery.